Journal
GENES
Volume 13, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/genes13122366
Keywords
miRNAs; antibody therapeutics; anti-IL-4; IL-13 receptor; dupilumab; nasal polyposis; interleukins; T cells
Categories
Ask authors/readers for more resources
Dupilumab has been proven effective in treating diseases such as asthma and atopic dermatitis, and now its use as add-on therapy for patients with CRSwNP could lead to reduced remission time and improved quality of life. The study also showed that miRNAs may serve as potential biomarkers for immune modulation. Preliminary data indicated that dupilumab treatment led to a reduction in inflammation and modulation of specific miRNAs related to proliferation, inflammation, and drug-resistance.
Already used for the treatment of some allergic and inflammatory diseases, such as asthma or atopic dermatitis, dupilumab has also been approved as add-on therapy for patients with CRSwNP, and it could represent the keystone to reducing the remission time as well as to improve healing and quality of life. On the other hand, the role of miRNAs as potential biomarkers of immune modulation is emerging. We analyzed the effects of a short-time treatment with dupilumab in patients with CRSwNP, analyzing the immune response modification as well as miRNAs modulations. First, in this early observation stage, all patients experienced remarkable improvement and were clinically stable. Indeed, we observed a significant decrease in CD4+ T cells and a significant reduction in total IgE (p < 0.05) and serum IL-8 levels (p < 0.01), indicating a reduction in the general inflammatory condition. In addition, we analyzed a panel of about 200 circulating miRNAs. After treatment, we noted a significant downregulation of hsa-mir-25-3p (p-value = 0.02415) and hsa-mir-185-5p (p-value = 0.04547), two miRNAs involved in the proliferation, inflammation, and dug-resistance, in accordance with the clinical status of patients. All these preliminary data aimed to identify new biomarkers of prognosis, identifiable with non-invasive procedures for patients. Further, these patients are still under observation, and others with different levels of responsiveness to treatment need to be enrolled to increase the statistical data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available